HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors.

Abstract
Giroline (RP 49532A) is a new protein-synthesis inhibitor with broad antitumor activity in experimental models. In the present phase I study, Giroline was given by 24-h i.v. infusion every 3 weeks at doses ranging from 3 to 15 mg/m2 to 12 patients with advanced refractory solid tumors. The dose-limiting toxic effects were delayed hypotension and severe asthenia. The maximum tolerated dose (MTD) was 15 mg/m2. Transient nausea and vomiting during infusion were reported at all dose levels. Mild reversible prolongation of prothrombin time and activated partial thromboplastin time was observed in most patients at dose levels above 3 mg/m2. No antitumor activity was observed. The toxicity profile of Giroline precludes further evaluation in cancer patients.
AuthorsG Catimel, R Coquard, J P Guastalla, Y Merrouche, N Le Bail, M K Alakl, A Dumortier, M Foy, M Clavel
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 35 Issue 3 Pg. 246-8 ( 1995) ISSN: 0344-5704 [Print] Germany
PMID7805184 (Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Imidazoles
  • Propanolamines
  • Protein Synthesis Inhibitors
  • girodazole
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage, adverse effects, therapeutic use)
  • Asthenia (chemically induced)
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Hypotension (chemically induced)
  • Imidazoles (administration & dosage, adverse effects, therapeutic use)
  • Infusions, Intravenous
  • Male
  • Middle Aged
  • Nausea (chemically induced)
  • Neoplasms (drug therapy)
  • Propanolamines (administration & dosage, adverse effects, therapeutic use)
  • Protein Synthesis Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Vomiting (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: